Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.41 |
| ▸ | TUBB | P07437 | 3/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727715 | 0.80 | TNFRSF1A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6040865 | 0.78 | KDM4C (0.41) | SMN1; SMN2RXRAALDH1A1KMT2ACA12 | |
| SCHEMBL6040615 | 0.78 | TNFRSF1A (0.40) | RAB9AMAPK1RXRAALDH1A1HTT | |
| SCHEMBL6040925 | 0.77 | RAB9A (0.48) | ECE1RAB9ASMN1; SMN2MAPTNPC1 | |
| SCHEMBL6040652 | 0.76 | AR (0.43) | RAB9AMAPK1RXRAALDH1A1HTT | |
| SCHEMBL6040699 | 0.75 | ABCG2 (0.55) | TDP1 | |
| SCHEMBL6040692 | 0.75 | ABCG2 (0.55) | TDP1 | |
| SCHEMBL6040496 | 0.75 | TSHR (0.44) | RAB9ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6040796 | 0.75 | TNFRSF1A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6040676 | 0.75 | ROCK2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | claimed |
| JP-2005516941-A | — | — | 2005-06-09 | — | — | JP | claimed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040181075-A1 | Process of making chalcone derivatives | GENERAL ELECTRIC COMPANY | 2004-09-16 | — | — | US | claimed |
| WO-2004056727-A2 | PROCESS OF MAKING CHALCONE DERIVATIVES | ATHEROGENICS, INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040181075-A1 | Process of making chalcone derivatives | GENERAL ELECTRIC COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056727-A2 | PROCESS OF MAKING CHALCONE DERIVATIVES | ATHEROGENICS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | ECE1 24/4885RAB9A 1137/4885SMN1; SMN2 2931/4885 |
| US-20040181075-A1 | Process of making chalcone derivatives | CYP2B6, LSS, CYP2E1 | ECE1 860/4885RAB9A 3448/4885SMN1; SMN2 4274/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | ECE1 17/4885RAB9A 998/4885SMN1; SMN2 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.